Evidence map›Paper›PMID 34321461›Full record

ArticleCell death & disease2021

Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2.

Dong Ha Kim, Hyojeong Park, Yun Jung Choi, Myoung-Hee Kang, Tae-Keun Kim, Chan-Gi Pack, Chang-Min Choi, Jae Cheol Lee, Jin Kyung Rho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dong Ha KimAsan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
Hyojeong ParkDepartment of Biomedical Sciences, Asan Medical Center, AMIST, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
Yun Jung ChoiAsan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
Myoung-Hee KangAsan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.ORCID 0000-0002-0182-9721
Tae-Keun KimAsan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
Chan-Gi PackDepartment of Convergence Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.ORCID 0000-0002-6578-3099
Chang-Min ChoiDepartment of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
Jae Cheol Lee *Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea. jclee@amc.seoul.kr.
Jin Kyung Rho *Department of Convergence Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea. jkrho@amc.seoul.kr.
Ulsan College · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2021IP0058Korea Health Industry Development Institute (KHIDI) HA16C0023National Research Foundation of Korea (NRF) 2019R1A2C2006054National Research Foundation of Korea (NRF) 2019R1C1C1007262
6 · The paper itself

Abstract

Tumor-derived exosomes (TEXs) contain enriched miRNAs, and exosomal miRNAs can affect tumor growth, including cell proliferation, metastasis, and drug resistance through cell-to-cell communication. We investigated the role of exosomal miR-1260b derived from non-small cell lung cancer (NSCLC) in tumor progression. Exosomal miR-1260b induced angiogenesis by targeting homeodomain-interacting protein kinase-2 (HIPK2) in human umbilical vein endothelial cells (HUVECs). Furthermore, exosomal miR-1260b or suppression of HIPK2 led to enhanced cellular mobility and cisplatin resistance in NSCLC cells. In patients with NSCLC, the level of HIPK2 was significantly lower in tumor tissues than in normal lung tissues, while that of miR-1260b was higher in tumor tissues. HIPK2 and miR-1260b expression showed an inverse correlation, and this correlation was strong in distant metastasis. Finally, the expression level of exosomal miR-1260b in plasma was higher in patients with NSCLC than in healthy individuals, and higher levels of exosomal miR-1260b were associated with high-grade disease, metastasis, and poor survival. In conclusion, exosomal miR-1260b can promote angiogenesis in HUVECs and metastasis of NSCLC by regulating HIPK2 and may serve as a prognostic marker for lung cancers.

Indexed as

ApoptosisBase SequenceCarcinoma, Non-Small-Cell LungCarrier ProteinsCell Line, TumorCell MovementCisplatinExosomesGene Expression Regulation, NeoplasticHumansHuman Umbilical Vein Endothelial CellsLung NeoplasmsMicroRNAsNeoplasm InvasivenessNeoplasm MetastasisNeovascularization, PathologicCarrier ProteinsCisplatinHIPK2 protein, humanMicroRNAsMIRN1260 microRNA, humanProtein Serine-Threonine KinasesVascular Endothelial Growth Factor A

Identifiers

PMID34321461
PMCPMC8319168
OpenAlexW3184310928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.